WALTHAM, Mass.–(BUSINESS WIRE)–The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 13, 2026 to all shareholders of record at the close of business on October 23, 2026. About Revvity At Revvity,… … […]
The biotech exceeded its original IPO target as it awaits a critical regulatory decision that could come early next year. … […]
WATERTOWN, Mass., July 31, 2026 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today provided a business update… … […]
The 15,000-square-foot Wilmington site will support manufacturing of the eShunt System, a minimally invasive treatment for communicating hydrocephalus. … […]
CAMBRIDGE, Mass., July 30, 2026 /PRNewswire/ — Apnimed, Inc. (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced… … […]
Scientific breakthroughs have the power to change lives, but science itself is not the only contributor to their impact. The 2026 BiotechTV U.S. Science Summit, presented by title sponsors MassBio and BIO, brought together biotech leaders, researchers, investors and science communicators to discuss the opportunities and challenges shaping the future… … […]
MassBio CEO & President Kendalle Burlin O’Connell originally posted this update to LinkedIn. Washington is clearing its desk before August recess. The Senate has stacked a final round of hearings, including several in the biotech space, the SEC sent Congress its annual capital formation recommendations, and the administration proposed new… … […]
New findings could help researchers design synthetic catalysts that convert nitrogen gas to ammonia, a key step in fertilizer production. … […]
Leveraging 30+ validated PCC programs and over 12 years of model development experience to create a large-scale real-world “blind test” for frontier AI and foundation models, with a transparent public leaderboard. CAMBRIDGE, Mass., July 30, 2026 /PRNewswire/ — As general-purpose and… … […]
LTG-001 achieved the primary endpoint of the Phase IIb LTG-001-010 trial (NCT07102459) by achieving better-than-placebo scores in the time-weighted sum of the pain-intensity difference (SPID) over the 48-hour treatment period (SPID48), based on the 0-10 range of scores of the Numeric Pain Rating Scale, with higher SPID48 values indicating greater… … […]
Copyright © 2026 Biotech Networks, LLC
